LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Their core work

LMU Munich is one of Germany's leading full-spectrum research universities, with particular depth in life sciences, biomedicine, and fundamental physics. Their H2020 portfolio reveals strong capabilities in molecular biology (DNA nanotechnology, epigenetics, chromatin research), clinical and translational medicine (stroke, cancer immunotherapy, Alzheimer's disease), and advanced materials science (perovskites, plasmonics). They serve as both a training hub through extensive Marie Skłodowska-Curie fellowships and a frontier research powerhouse through a high concentration of ERC grants, making them a dual-purpose partner for both capacity building and discovery-driven projects.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), LMU's work centered on foundational molecular science — oligonucleotides, self-assembly, biomarkers, atherosclerosis, and microbiome research — reflecting a classic basic-science profile. By the later period (2019–2022), their portfolio shifted noticeably toward translational and applied biomedical research: traumatic brain injury, cancer immunotherapy, AI-assisted diagnostics, and clinical trials became dominant themes. There is also a visible expansion into advanced imaging (super-resolution microscopy, diffusion MRI) and materials science (perovskites, plasmonics), suggesting the university is bridging fundamental discoveries toward technological applications.

LMU is moving from fundamental molecular research toward clinical translation and AI-enabled biomedicine, making them an increasingly relevant partner for health-tech and precision medicine consortia.

How they like to work

LMU leads slightly more projects than it joins (159 coordinator vs 140 participant roles), which is unusual for a university — most are net participants. This signals strong grant-writing capacity and willingness to take on administrative leadership. With 1,379 unique consortium partners across 74 countries, they operate as a major European hub with an exceptionally wide network, rather than relying on a tight circle of repeat collaborators. For potential partners, this means LMU brings both coordination experience and access to a vast web of established relationships across disciplines and geographies.

LMU has collaborated with 1,379 unique partners across 74 countries, placing it among the most connected universities in H2020. Their network spans well beyond Europe into global partnerships, with particular density in Western European research hubs.

What sets them apart

LMU stands out through its extraordinary concentration of ERC grants (59 Starting + 23 Consolidator grants alone), which signals world-class individual researchers choosing this institution as their host. Unlike many large universities that participate broadly but shallowly, LMU's 303-project portfolio shows genuine depth in molecular biosciences and translational medicine, backed by €223M in EC funding. For consortium builders, LMU offers a rare combination: the scientific firepower of a top-5 European research university with proven coordination experience and a network spanning 74 countries.

Highlights from their portfolio

• DIVI
  Largest single EC contribution at nearly €1.9M, focused on ultrafast atomic-scale imaging — a technically ambitious project at the physics-materials interface.
• Highland Connections
  €1.5M ERC grant coordinated by LMU on highland Asian connectivity — demonstrates the university's breadth beyond STEM into humanities and social sciences.
• CATCH ME
  Major translational health project on atrial fibrillation linking disease mechanisms to personalized therapy, exemplifying LMU's shift toward clinical application.